By Michele Maatouk
Date: Tuesday 16 May 2023
(Sharecast News) - Horizon Therapeutics tumbled in pre-market trade on Tuesday following a report that its $27.8bn takeover by Amgen will be challenged by federal regulators.
SEP cashes in as US giant Amgen buys cancer drug... | 26-Jan-2011 | The Scotsman |
Amgen Buys a Cancer Drug Maker | 25-Jan-2011 | New York Times |
Tech Ticker | 16-Dec-2010 | BayArea.com |
Amgen drug delayed spread of prostate cancer to ... | 15-Dec-2010 | LA Times |
Business Briefing | 24-Dec-2009 | LA Times |
Currency | US Dollars |
Share Price | $ 290.29 |
Change Today | $ 0.96 |
% Change | 0.33 % |
52 Week High | $337.38 |
52 Week Low | $258.59 |
Volume | 1,932,645 |
Shares Issued | 536.90m |
Market Cap | $155,857m |
RiskGrade | 100 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 15 |
Sell | 2 |
Strong Sell | 1 |
Total | 31 |
Time | Volume / Share Price |
16:00 | 477,550 @ $290.29 |
15:59 | 971 @ $290.20 |
15:59 | 222 @ $290.20 |
15:59 | 265 @ $290.21 |
15:59 | 771 @ $290.21 |
You are here: research